The Alaska Native Medical Center Transfusion Lookback Program was supported in part by a grant entitled “HCV Epidemiology and Research Laboratory in Alaska” from the Alaska Science & Technology Foundation (Agreement 99-4-113).
Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992
Article first published online: 3 MAY 2005
Volume 45, Issue 6, pages 1020–1026, June 2005
How to Cite
Williams, J. L., Cagle, H. H., Christensen, C. J., Fox-Leyva, L. K. and McMahon, B. J. (2005), Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Transfusion, 45: 1020–1026. doi: 10.1111/j.1537-2995.2005.04280.x
- Issue published online: 31 MAY 2005
- Article first published online: 3 MAY 2005
- Received for publication July 6, 2004; revision received November 23, 2004, and accepted November 18, 2004.
BACKGROUND: The Centers for Disease Control and Prevention recommend hepatitis C virus (HCV) antibody (anti-HCV) screening for persons who received blood products before July 1992. A general transfusion lookback program was implemented to identify, counsel, and screen persons who received transfusions at the Alaska Native Medical Center between January 1980 and July 1992.
STUDY DESIGN AND METHODS: Hard-copy transfusion records data were entered, and available databases were queried to identify deceased patients and the mailing address of those living. Patients were notified by letter of their HCV risk and encouraged to seek counseling and testing. Serum samples were screened for anti-HCV and HCV RNA, and program costs were estimated.
RESULTS: Overall, 3169 transfusion recipients were identified, with 1356 (43%) living and targeted for notification. Of 764 patients notified and screened by this program, 41 (5%) were anti-HCV–positive and 19 (2%) were HCV RNA–positive. There was a higher probability of detecting anti-HCV with each subsequent increase of a transfusion event. Among 298 lookback patients, 33 percent were unaware of having received a blood transfusion. The estimated cost per person sent notification was US$57 and to detect an anti-HCV–positive case it was US$3146.
CONCLUSION: This general transfusion lookback program successfully notified and screened patients at a reasonable cost. Further investigation would be helpful in determining the role these programs or other measures could play in promoting HCV screening in persons receiving transfusions before July 1992, especially among those who are unaware of their transfusion history.